Pricing overview of domestic ibrutinib/ibrutinib

Ibrutinib/Ibrutinib, an innovative targeted drug, plays a vital role in the fight against malignant tumors such as B-cell leukemia and lymphoma by precisely inhibiting Bruton's tyrosine kinase (BTK). Its unique mechanism enables ibrutinib to induce apoptosis in cancer cells, thereby bringing new life to patients. In addition to showing excellent efficacy in the treatment of Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, and small lymphocytic lymphoma, ibrutinib is also used in the treatment of chronic graft-versus-host disease.

In China, the original ibrutinib drug was approved by the State Food and Drug Administration in the form of capsules and officially launched on the market in August 2017. This landmark event has brought a new treatment strategy to domestic patients suffering from blood system diseases, significantly improved the treatment effect, and also substantially improved the quality of life of patients. With the advice and guidance of doctors, eligible patients can now easily obtain and use this drug.

It is worth noting that ibrutinib has entered the Class B medical insurance reimbursement list, but only patients who meet specific indications can enjoy reimbursement benefits. Currently, the selling price of 140mg*90 ibrutinib capsules widely circulated in the market is approximately RMB 10,000. As for the prices of domestic generic drugs, there is currently no clear market data disclosure.

In comparison, the price of original drugs in overseas markets appears to be more expensive, and products of the same specifications may cost as much as more than 10,000 US dollars. However, there are also more affordable generic ibrutinib options in overseas markets. The selling price of each box may only fluctuate between a few hundred to 1,000 yuan (the specific price is affected by factors such as exchange rate changes). This price difference provides patients with more choices.